<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602862</url>
  </required_header>
  <id_info>
    <org_study_id>Sorafenib-mAbs</org_study_id>
    <nct_id>NCT00602862</nct_id>
  </id_info>
  <brief_title>Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250</brief_title>
  <official_title>The Effect of Sorafenib (Nexavar®) on 111-Indium Labeled Chimeric Monoclonal Antibody G250 or 111-Indium Labeled Bevacizumab (Avastin®) Uptake in Patients With Clear Cell RCC (ccRCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sorafenib is a tyrosine kinase inhibitor that is registered for the treatment of metastasized
      clear cell Renal Cell Carcinoma (ccRCC). It inhibits signal transduction of the Vascular
      Endothelial Growth Factor Receptor (VEGFR) and the Platelet Derived Growth Factor Receptor
      (PDGFR). In the tumorigenesis of ccRCC, VEGF and PDGF are upregulated due to the defective
      Von-Hippel-Lindau (VHL) gene. CcRCC has a high Interstitial Fluid Pressure (IFP) and Tumor
      Microvascular Density (TMD), hampering the delivery of chemotherapeutics and monoclonal
      antibodies (mAbs). It was hypothesized that antiangiogenic compounds decrease tumor IFP and
      TMD, thus normalizing tumor vasculature, before diminishing tumor vasculature. Bevacizumab is
      an anti-VEGF mAb which depletes soluble VEGF from plasma, depriving VEGFR of its ligand.
      Chimeric monoclonal antibody cG250 recognizes carbonic anhydrase IX (CAIX), an antigen that
      is abundantly expressed in Renal Cell Carcinoma (RCC) and has limited expression in normal
      tissue. The aim of this study was to investigate the effect of Sorafenib on ccRCC physiology,
      by determining tumor uptake of 111In labeled cG250 or 111In labeled Bevacizumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effect of sorafenib treatment on 111In-cG250 uptake of the tumor</measure>
    <time_frame>pre-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the effect of sorafenib treatment on 111In-bevacizumab uptake of the tumor</measure>
    <time_frame>pre-surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemical analysis of CA-IX expression, (p)VHL status, HIF1-a, VEGF and PDGF expression, apoptosis and necrosis of surgical specimen</measure>
    <time_frame>within 6 months post-surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/10mg 111In-cG250. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Whole-body scintigraphic images are recorded 1 week after the injection to calculate tumor uptake. Hereafter, patients will undergo surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib 200 mg 2dd2 po for 4 weeks before surgery</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Bevacizumab</other_name>
    <other_name>Avastin</other_name>
    <other_name>Nexavar</other_name>
    <other_name>cG250</other_name>
    <other_name>Rencarex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>111Indium-bevacizumab</intervention_name>
    <description>100 MBq / 1 mg 111Indium/bevacizumab iv</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>avastin</other_name>
    <other_name>indium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>111Indium-cG250</intervention_name>
    <description>100 MBq / 10 mg 111Indium-cG250 iv</description>
    <arm_group_label>2</arm_group_label>
    <other_name>rencarex</other_name>
    <other_name>indium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal cell carcinoma patients planned for surgery (nephrectomy/metastasectomy)

          -  Karnofsky &gt; 70 %

          -  Laboratory values within 14 days prior to start:

               -  White blood cells (WBC) &gt; 3.5 x 109/L

               -  Platelets &gt; 100 x 109/L

               -  Hemoglobin &gt; 6 mmol/L

               -  Total bilirubin &lt; 1.5 upper limit of normal (ULN)

               -  ASAT, ALAT &lt; 2.5 x ULN (&lt;5 x in case of liver metastases)

               -  Lactate dehydrogenase (LDH) &gt; 1.5. ULN

               -  Serum creatinine &lt; 2 x ULN

               -  Amylase and Lipase &lt; 1.5 ULN

          -  Negative pregnancy test in premenopausal women

          -  Age over 18 years

          -  Signed informed consent

          -  Life expectancy &gt; 24 weeks

          -  PT/APTT/ INR &lt; 1.5 ULN

          -  No current use of coumarin derivatives

        Exclusion Criteria:

          -  Known subtype other than clear cell RCC

          -  Pre-exposure to murine/chimeric antibody therapy

          -  Known brain metastases

          -  Untreated hypercalcemia

          -  Uncontrolled hypertension

          -  Concurrent therapeutic anticoagulation

          -  Chemotherapy, immunotherapy or radiation therapy within 4 weeks prior to start of
             study. Palliative limited field external radiation for fracture prevention is allowed

          -  Cardiac arrhythmias requiring antiarrhythmics (beta-blockers, digoxin), symptomatic
             coronary artery disease and congestive heart failure New York Heart Association III or
             IV.

          -  Previous malignancy &lt; 2 years prior to the study (except for cervical carcinoma in
             situ, basal cell carcinoma, or superficial bladder tumours (Ta, Tis, T1)

          -  Any medical condition present that in the opinion of the investigator will affect
             patients' clinical status. No other concurrent malignancy except nonmetastatic
             nonmelanoma skin cancer or carcinoma in situ of the cervix.

          -  Active clinically serious bacterial or fungal infections (&lt; grade 2 NCI-CTC version 3)

          -  Known history of Human Immunodeficiency virus (HIV) infection or chronic hepatitis
             B/C.

          -  Prior use of Raf-kinase inhibitors, MEK and Farnesyl transferase inhibitors

          -  Prior use of Bevacizumab and all other drugs that target VEGF/ VEGF-receptors

          -  Use of antiepileptic drugs

          -  Pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WJG Oyen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PFA Mulders, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>November 29, 2013</last_update_submitted>
  <last_update_submitted_qc>November 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angiogenesis inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

